Fate Therapeutics Hosts Immunotherapy Focus Session at Stem Cell Research Annual Meeting

Fate Therapeutics Hosts Immunotherapy Focus Session at Stem Cell Research Annual Meeting
0
(0)

Fate Therapeutics hosted a focus session at the 2016 Annual Meeting of the International Society for Stem Cell Research (ISSCR) that included a detailed review of induced pluripotent stem cell (iPSC) technology and highlighted the company’s advancements in the development of recently engineered NK- and T-cell cancer immunotherapies.

The focus session, “Fighting Cancer with Off-the-Shelf iPSC Immunotherapies,” covered topics from basic research to clinical development while discussing the genetic engineering of pluripotent cells (stem cells that can differentiate into several types of tissues), the derivation and expansion of single pluripotent cell clones, and the generation of ready-made NK- and T-cells, with improved functions from pluripotent cells. Participating speakers included:

  • Bob Valamehr, Ph.D. (Fate Therapeutics’ executive director of Cancer Immunotherapy);
  • Dan Kaufman, M.D., Ph.D. (University of California San Diego professor of medicine and director of the Cell Therapy Program);
  • Daniel Shoemaker, Ph.D. (Fate Therapeutics’ chief scientific officer);
  • Michel Sadelain, M.D., Ph.D. (director of the Center for Cell Engineering and Stephen and Barbara Friedman Chair at Memorial Sloan-Kettering Cancer Center);
  • Rudolf Jaenisch, M.D. (professor of biology at MIT and member of the Whitehead Institute for Biomedical Research).

Fate Therapeutics is a biopharma based in San Diego dedicated to developing programmed cellular immunotherapies for cancer and immune disorders. The company’s pipeline includes immuno-oncology programs, ready-made NK- and T-cell cancer immunotherapies derived from induced pluripotent cells and immuno-regulatory programs (like hematopoietic cell immunotherapies to protect the immune systems of patients who need a hematopoietic cell transplant).

According to a press release, some of these immunotherapies will be presented at the ISSCR Annual Meeting:

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • Tecentriq and FDA approval
  • Keytruda
  • Opdivo-Cabometyx combo
  • Health Canada approves Opdivo-Yervoy-chemo for metastatic NSCLC

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?